Mereo Biopharma

MREO
0.26005.45% ( -0.0150 )
Closed: Nov 20, 16:00:00 (EDT)

Financials

Q3 FY2026 EarningsQ3 FY26 results were largely in-line with consensus on the bottom line, with a Net Loss of -$5.86M vs. the -$5.80M (GBP-equivalent) expected. Revenue of $0.8M beat the $0.0M consensus, driven by non-recurring collaboration items. A 51% YoY reduction in R&D expenses and an 18% YoY decrease in G&A expenses reflect tight cost controls as the company extends its cash runway to late-2027. Management confirmed ongoing FDA/EMA interactions for core programs setrusumab and alvelestat, with a Phase 3 initiation for alvelestat targeted for early 2027.

Financial report interval: 2026.06.30 - 2026.09.30

Overview: Mereo Biopharma(MREO) the Revenue is 793.77 K (--%), Beat estimate;the EBIT is -6.17 M (+39.72%), Beat estimate;the EPS is -0.0099 (+2.96%), Miss estimate.

Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITExceed expectations
-0.01B39.72%
-0.01B20.21%
+0.00B19.51%
EPSMiss expectations
-0.00992.96%
-0.00939.19%
-0.00066.23%

Upcoming earnings report - FY2026 Annual Earning Release

Available dateMar 19, 2027
Estimate Revenue791.56K
Estimate EBIT--
Estimate EPS-0.0533

Revenue

ActualEstimateUnit: USD
Quarterly

EBIT

ActualEstimateUnit: USD
Quarterly

Net income

ActualEstimateUnit: USD
Quarterly

EPS

ActualEstimateUnit: USD
Quarterly